177 related articles for article (PubMed ID: 26888994)
1. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.
Lopez-Chiriboga AS; Komorowski L; Kümpfel T; Probst C; Hinson SR; Pittock SJ; McKeon A
Neurology; 2016 Mar; 86(11):1009-13. PubMed ID: 26888994
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
Yoshikura N; Kimura A; Fukata M; Fukata Y; Yokoi N; Harada N; Hayashi Y; Inuzuka T; Shimohata T
J Neuroimmunol; 2018 Jun; 319():63-67. PubMed ID: 29685291
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2.
Ruiz-García R; Martínez-Hernández E; Joubert B; Petit-Pedrol M; Pajarón-Boix E; Fernández V; Salais L; Del Pozo M; Armangué T; Sabater L; Dalmau J; Graus F
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826987
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
Honorat JA; Lopez-Chiriboga AS; Kryzer TJ; Komorowski L; Scharf M; Hinson SR; Lennon VA; Pittock SJ; Klein CJ; McKeon A
Neurology; 2019 Sep; 93(10):e954-e963. PubMed ID: 31371564
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against metabotropic glutamate receptor type 1 in a toddler with acute cerebellitis.
Bien CG; Braig S; Bien CI
J Neuroimmunol; 2020 Nov; 348():577366. PubMed ID: 32861169
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic neuronal intermediate filament autoimmunity.
Basal E; Zalewski N; Kryzer TJ; Hinson SR; Guo Y; Dubey D; Benarroch EE; Lucchinetti CF; Pittock SJ; Lennon VA; McKeon A
Neurology; 2018 Oct; 91(18):e1677-e1689. PubMed ID: 30282771
[TBL] [Abstract][Full Text] [Related]
7. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis.
Spatola M; Petit Pedrol M; Maudes E; Simabukuro M; Muñiz-Castrillo S; Pinto AL; Wandinger KP; Spiegler J; Schramm P; Dutra LA; Iorio R; Kornblum C; Bien CG; Höftberger R; Leypoldt F; Titulaer MJ; Sillevis Smitt P; Honnorat J; Rosenfeld MR; Graus F; Dalmau J
Neurology; 2020 Dec; 95(22):e3012-e3025. PubMed ID: 32928978
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.
Sillevis Smitt P; Kinoshita A; De Leeuw B; Moll W; Coesmans M; Jaarsma D; Henzen-Logmans S; Vecht C; De Zeeuw C; Sekiyama N; Nakanishi S; Shigemoto R
N Engl J Med; 2000 Jan; 342(1):21-7. PubMed ID: 10620645
[No Abstract] [Full Text] [Related]
10. Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers.
McKeon A; Shelly S; Zivelonghi C; Basal E; Dubey D; Flanagan E; Madhavan AA; Mariotto S; Toledano M; Tracy JA; Zekeridou A; Pittock SJ
Ann Clin Transl Neurol; 2021 Feb; 8(2):425-439. PubMed ID: 33369283
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?
Marignier R; Chenevier F; Rogemond V; Sillevis Smitt P; Renoux C; Cavillon G; Androdias G; Vukusic S; Graus F; Honnorat J; Confavreux C
Arch Neurol; 2010 May; 67(5):627-30. PubMed ID: 20457964
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma.
Iorio R; Damato V; Mirabella M; Vita MG; Hulsenboom E; Plantone D; Bizzarro A; Del Grande A; Sillevis Smitt PA
J Neuroimmunol; 2013 Oct; 263(1-2):155-8. PubMed ID: 23958353
[TBL] [Abstract][Full Text] [Related]
13. 'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII.
Jarius S; Wildemann B
J Neuroinflammation; 2015 Sep; 12():166. PubMed ID: 26377085
[TBL] [Abstract][Full Text] [Related]
14. Neurochondrin neurological autoimmunity.
Shelly S; Kryzer TJ; Komorowski L; Miske R; Anderson MD; Flanagan EP; Hinson SR; Lennon VA; Pittock SJ; McKeon A
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31511329
[TBL] [Abstract][Full Text] [Related]
15. Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects.
Landa J; Guasp M; Petit-Pedrol M; Martínez-Hernández E; Planagumà J; Saiz A; Ruiz-García R; García-Fernández L; Verschuuren J; Saunders-Pullman R; Ramirez-Gómez L; Geschwind MD; Dalmau J; Sabater L; Graus F
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33144342
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies.
Coesmans M; Smitt PA; Linden DJ; Shigemoto R; Hirano T; Yamakawa Y; van Alphen AM; Luo C; van der Geest JN; Kros JM; Gaillard CA; Frens MA; de Zeeuw CI
Ann Neurol; 2003 Mar; 53(3):325-36. PubMed ID: 12601700
[TBL] [Abstract][Full Text] [Related]
17. Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia.
Ishibashi K; Miura Y; Ishikawa K; Zhang MR; Toyohara J; Ishiwata K; Ishii K
J Neurol; 2016 Nov; 263(11):2179-2187. PubMed ID: 27502082
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.
Damato V; Papi C; Spagni G; Evoli A; Silvestri G; Masi G; Sabatelli E; Campetella L; McKeon A; Andreetta F; Riso V; Monte G; Luigetti M; Primiano G; Calabresi P; Iorio R
Eur J Neurol; 2022 Feb; 29(2):564-572. PubMed ID: 34710286
[TBL] [Abstract][Full Text] [Related]
19. GABAB receptor autoantibody frequency in service serologic evaluation.
Jeffery OJ; Lennon VA; Pittock SJ; Gregory JK; Britton JW; McKeon A
Neurology; 2013 Sep; 81(10):882-7. PubMed ID: 23925760
[TBL] [Abstract][Full Text] [Related]
20. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients.
Tobin WO; Lennon VA; Komorowski L; Probst C; Clardy SL; Aksamit AJ; Appendino JP; Lucchinetti CF; Matsumoto JY; Pittock SJ; Sandroni P; Tippmann-Peikert M; Wirrell EC; McKeon A
Neurology; 2014 Nov; 83(20):1797-803. PubMed ID: 25320100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
